þ
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
Delaware
|
|
33-0325826
|
(State
or other jurisdiction of incorporation
or
organization)
|
|
(I.R.S. Employer Identification Number)
|
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨
|
Smaller
reporting company x
|
(Do
not check if a smaller reporting company)
|
|
|
Page
|
|
PART
I
|
FINANCIAL
INFORMATION
|
||
|
|||
Item 1.
|
Financial
Statements
|
||
Condensed
Consolidated Balance Sheets at September 26, 2008 (unaudited)
and March
31, 2008
|
3
|
||
Condensed
Consolidated Statements of Operations for the three-month and
six-month
periods ended September 26, 2008 and September 28, 2007(unaudited)
|
4
|
||
Condensed
Consolidated Statements of Cash Flows for the three-month periods
ended
September 26, 2008 and September 28, 2007 (unaudited)
|
5
|
||
Notes
to Condensed Consolidated Financial Statements
|
6
|
||
|
|||
Item 2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
17
|
|
|
|||
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
26
|
|
|
|||
Item 4.
|
Controls
and Procedures
|
26
|
|
|
|||
PART
II
|
OTHER
INFORMATION
|
||
Item
1
|
Legal
Proceedings
|
27
|
|
Item
1A
|
Risk
Factors
|
27
|
|
Item
2
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
27
|
|
Item
3
|
Defaults
Upon Senior Securities
|
27
|
|
Item
4
|
Submission
of Matters to a Vote of Security Holders
|
27
|
|
Item
5
|
Other
Information
|
27
|
|
Item 6.
|
Exhibits
|
28
|
|
Exh.
31.1 Section 302 Certification of Chief Executive Officer
|
|||
Exh.
31.2 Section 302 Certification of Chief Financial Officer
|
|||
Exh.
32.1 Section 906 Certification of Chief Executive Officer
|
|||
Exh.
32.2 Section 906 Certification of Chief Financial Officer
|
|||
Signatures
|
29
|
September 26,
2008
(Unaudited)
|
March 31, 2008
|
||||||
ASSETS
|
|||||||
Current
assets:
|
|||||||
Cash
and cash equivalents
|
$
|
389,000
|
$
|
82,000
|
|||
Restricted
cash
|
500,000
|
1,500,000
|
|||||
Accounts
receivable, net
|
5,188,000
|
3,202,000
|
|||||
Inventories,
net
|
4,309,000
|
4,131,000
|
|||||
Prepaid
expenses and other current assets
|
478,000
|
195,000
|
|||||
Total
current assets
|
10,864,000
|
9,110,000
|
|||||
Equipment
and leasehold improvements, net
|
4,599,000
|
4,757,000
|
|||||
Goodwill
|
4,579,000
|
4,579,000
|
|||||
Intangibles
and patents, net
|
9,916,000
|
10,871,000
|
|||||
Other
assets
|
385,000
|
386,000
|
|||||
TOTAL
ASSETS
|
$
|
30,343,000
|
$
|
29,703,000
|
|||
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
|||||||
Current
liabilities
|
|||||||
Line
of credit
|
$
|
1,363,000
|
$
|
1,300,000
|
|||
Accounts
payable
|
1,420,000
|
1,339,000
|
|||||
Accrued
expenses
|
1,962,000
|
1,254,000
|
|||||
Current
portion of long-term debt-related parties
|
1,851,000
|
900,000
|
|||||
Current
portion of long term debt- capital lease obligations
|
—
|
460,000
|
|||||
Current
portion of long term debt- bank term loan
|
398,000
|
—
|
|||||
Current
portion of long-term debt - MEDC
|
322,000
|
62,000
|
|||||
Total
current liabilities
|
7,316,000
|
5,315,000
|
|||||
Long-term
debt, less current portion - MEDC
|
1,989,000
|
2,249,000
|
|||||
Long-term
debt, less current portion - capital lease obligations
|
—
|
1,457,000
|
|||||
Long-term
debt, less current portion - bank term loan
|
1,338,000
|
—
|
|||||
Long-term
debt, less current portion - related parties
|
—
|
951,000
|
|||||
Total
liabilities
|
10,643,000
|
9,972,000
|
|||||
Shareholders'
equity:
|
|||||||
Class
A common
stock,
$.001 par value, 100,000,000 authorized; September 26, 2008 – 24,076,216
shares issued and outstanding, March 31, 2008– 23,977,678 shares issued
and outstanding.
|
24,000
|
24,000
|
|||||
Class
B common
stock,
$.001 par value; 4,420,113 shares authorized; September 26, 2008
and March
31, 2008 - 31,691 issued and outstanding.
|
—
|
—
|
|||||
Additional
paid-in capital
|
52,298,000
|
52,150,000
|
|||||
Accumulated
deficit
|
(32,622,000
|
)
|
(32,443,000
|
)
|
|||
Total
shareholders' equity
|
19,700,000
|
19,731,000
|
|||||
TOTAL
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
$
|
30,343,000
|
$
|
29,703,000
|
Three Months Ended
|
Six Months Ended
|
||||||||||||
September 26,
2008
|
September 28,
2007
|
September 26,
2008
|
September 28,
2007
|
||||||||||
Sales,
net
|
$
|
8,188,000
|
$
|
6,529,000
|
$
|
15,958,000
|
$
|
12,674,000
|
|||||
Cost
of products sold
|
4,624,000
|
3,784,000
|
8,638,000
|
7,459,000
|
|||||||||
Gross
profit
|
3,564,000
|
2,745,000
|
7,320,000
|
5,215,000
|
|||||||||
Operating
expenses:
|
|||||||||||||
Research,
development and engineering
|
1,081,000
|
1,016,000
|
2,209,000
|
1,910,000
|
|||||||||
Sales
and marketing
|
710,000
|
559,000
|
1,330,000
|
1,205,000
|
|||||||||
General
and administrative
|
1,432,000
|
1,180,000
|
2,515,000
|
2,353,000
|
|||||||||
Amortization
Expense
|
518,000
|
490,000
|
1,044,000
|
980,000
|
|||||||||
Wafer
fabrication relocation expenses
|
48,000
|
268,000
|
208,000
|
611,000
|
|||||||||
Total
operating expenses
|
3,789,000
|
3,513,000
|
7,306,000
|
7,059,000
|
|||||||||
(Loss)
Income from operations
|
(225,000
|
)
|
(768,000
|
)
|
14,000
|
(1,844,000
|
)
|
||||||
Other
income (expense):
|
|||||||||||||
Interest
income
|
12,000
|
26,000
|
28,000
|
47,000
|
|||||||||
Interest
expense
|
(83,000
|
)
|
(280,000
|
)
|
(164,000
|
)
|
(512,000
|
)
|
|||||
Interest
expense, related parties
|
(28,000
|
)
|
(42,000
|
)
|
(55,000
|
)
|
(99,000
|
)
|
|||||
Interest
expense, debt discount
|
—
|
(805,000
|
)
|
—
|
(1,373,000
|
)
|
|||||||
Other
income/(expense)
|
(2,000
|
)
|
12,000
|
(2,000
|
)
|
18,000
|
|||||||
Net
loss
|
$
|
(326,000
|
)
|
$
|
(1,857,000
|
)
|
$
|
(179,000
|
)
|
$
|
(3,763,000
|
)
|
|
Basic
and diluted loss per share
|
$
|
(0.01
|
)
|
$
|
(0.09
|
)
|
$
|
(0.01
|
)
|
$
|
(0.19
|
)
|
|
Weighted
average common shares outstanding
Basic
and diluted
|
24,060,000
|
19,906,000
|
24,035,000
|
19,584,000
|
Six Months Ended
|
|||||||
September 26, 2008
|
September 28, 2007
|
||||||
OPERATING
ACTIVITIES:
|
|||||||
Net
(loss)
|
$
|
(179,000
|
)
|
$
|
(3,763,000
|
)
|
|
Adjustment
to reconcile net (loss) to net cash (used in) operating
activities
|
|||||||
Depreciation
|
536,000
|
522,000
|
|||||
Amortization
|
1,044,000
|
980,000
|
|||||
Stock-based
compensation expense
|
100,000
|
133,000
|
|||||
Amortization,
convertible note discount
|
—
|
1,373,000
|
|||||
Amortization,
debt issue costs
|
—
|
60,000
|
|||||
Changes
in operating assets and liabilities:
|
|||||||
Accounts
receivable
|
(1,986,000
|
)
|
(544,000
|
)
|
|||
Inventories
|
(178,000
|
)
|
631,000
|
||||
Prepaid
expenses and other assets
|
(281,000
|
)
|
(130,000
|
)
|
|||
Accounts
payable and accrued expenses
|
789,000
|
138,000
|
|||||
Net
cash (used in) operating activities
|
(155,000
|
)
|
(600,000
|
)
|
|||
INVESTING
ACTIVITIES:
|
|||||||
Capital
expenditures
|
(378,000
|
)
|
(687,000
|
)
|
|||
Change
in restricted cash
|
1,000,000
|
—
|
|||||
Patent
expenditures
|
(89,000
|
)
|
(113,000
|
)
|
|||
Net
cash provided by (used in) investing activities
|
533,000
|
(800,000
|
)
|
||||
FINANCING
ACTIVITIES:
|
|||||||
Proceeds
from capital lease financing
|
—
|
433,000
|
|||||
Payments
on capital lease financing
|
(1,917,000
|
)
|
(153,000
|
)
|
|||
Proceeds
from bank term loan
|
1,736,000
|
—
|
|||||
Borrowings
on line of credit
|
63,000
|
159,000
|
|||||
Payments
on long-term debt – related parties
|
—
|
(550,000
|
)
|
||||
Net
proceeds from equity financing
|
—
|
4,321,000
|
|||||
Proceeds
from exercise of stock options
|
47,000
|
54,000
|
|||||
Proceeds
from MEDC term loan
|
—
|
357,000
|
|||||
Net
cash (used in) provided by financing activities
|
(71,000
|
)
|
4,621,000
|
||||
Net
increase in cash and cash equivalents
|
307,000
|
3,221,000
|
|||||
Cash
and cash equivalents at beginning of year
|
82,000
|
3,274,000
|
|||||
Cash
and cash equivalents at end of quarter
|
$
|
389,000
|
$
|
6,495,000
|
|||
Supplemental
disclosure of cash flow information:
|
|||||||
Cash
paid for income taxes
|
$
|
3,000
|
$
|
55,000
|
|||
Cash
paid for interest
|
$
|
150,000
|
$
|
438,000
|
•
|
The
time period that stock-based awards are expected to remain outstanding
has
been determined based on the average of the original award period
and the
remaining vesting period in accordance with the SEC’s short-cut approach
pursuant to SAB No. 107, “Disclosure
About Fair Value of Financial Statements”.
The expected term assumption for awards issued during the three-month
periods ended September 26, 2008 and September 28, 2007 was
6.3 years. As additional evidence develops from the employee’s stock
trading history, the expected term assumption will be refined to
capture
the relevant trends.
|
•
|
The
future volatility of the Company’s stock has been estimated based on the
weekly stock price from the acquisition date of Picometrix LLC
(May 2,
2005) to the date of the latest stock grant. The expected volatility
assumption for awards issued during the three-month periods ending
September 26, 2008 and September 28, 2007 was 40.8% and 49.9%,
respectively. As additional evidence develops, the future volatility
estimate will be refined to capture the relevant
trends.
|
•
|
A
dividend yield of zero has been assumed for awards issued during
the
three-month periods ended September 26, 2008 and September 28,
2007, based
on the Company’s actual past experience and the fact that Company does not
anticipate paying a dividend on its shares in the near
future.
|
•
|
The
Company has based its risk-free interest rate assumption for awards
issued
during the three-month periods ended September 26, 2008 and September
28,
2007 on the implied yield available on U.S. Treasury issues with an
equivalent expected term, which was 2.9% and 4.44% during the respective
periods.
|
•
|
The
forfeiture rate for awards issued during the three-month periods
ended
September 26, 2008 and September 28, 2007 were approximately 18.7%
and was
based on the Company’s actual historical forfeiture
trend.
|
Three months ended
|
Six months ended
|
||||||||||||
Sept. 26, 2008
|
Sept. 28, 2007
|
Sept. 26, 2008
|
Sept. 28, 2007
|
||||||||||
Cost
of Products Sold
|
$
|
3,000
|
$
|
5,000
|
$
|
5,000
|
$
|
11,000
|
|||||
Research
and Development expense
|
18,000
|
11,000
|
25,000
|
29,000
|
|||||||||
General
and Administrative expense
|
37,000
|
28,000
|
56,000
|
82,000
|
|||||||||
Sales
and Marketing expense
|
8,000
|
4,000
|
14,000
|
11,000
|
|||||||||
Total
Stock Based Compensation
|
$
|
66,000
|
$
|
48,000
|
$
|
100,000
|
$
|
133,000
|
Number of
Options
Outstanding
|
Weighted
Average Exercise
Price per Share |
Number of
Shares
Exercisable
|
Weighted
Average Exercise Price
per Share |
||||||||||
(000’s)
|
(000’s)
|
||||||||||||
Balance
of March 31, 2007
|
2,540
|
$
|
1.90
|
1,978
|
$
|
1.81
|
|||||||
Granted
|
115
|
$
|
1.80
|
||||||||||
Exercised
|
—
|
—
|
|||||||||||
Expired
|
—
|
—
|
|||||||||||
Balance
of June 29, 2007
|
2,655
|
$
|
1.88
|
2,192
|
$
|
1.82
|
|||||||
Granted
|
36
|
$
|
1.89
|
||||||||||
Exercised
|
(81
|
)
|
$
|
0.65
|
|||||||||
Expired
|
—
|
—
|
|||||||||||
Balance
of September 28, 2007
|
2,610
|
$
|
1.92
|
2,140
|
$
|
1.87
|
Number of
Options
Outstanding
|
Weighted
Average Exercise Price per Share |
Number of
Shares
Exercisable
|
Weighted
Average Exercise Price per Share |
||||||||||
(000’s)
|
(000’s)
|
||||||||||||
Balance
of March 31, 2008
|
2,619
|
$
|
1.92
|
2,198
|
$
|
1.87
|
|||||||
Granted
|
264
|
$
|
1.50
|
||||||||||
Exercised
|
—
|
—
|
|||||||||||
Expired
|
(38
|
)
|
$
|
1.25
|
|||||||||
Balance
of June 27, 2008
|
2,845
|
$
|
1.89
|
2,312
|
$
|
1.90
|
|||||||
Granted
|
28
|
$
|
1.76
|
||||||||||
Exercised
|
(42
|
)
|
$
|
0.88
|
|||||||||
Expired
|
(21
|
)
|
$
|
1.75
|
|||||||||
Balance
of September 26, 2008
|
2,810
|
$
|
1.91
|
2,343
|
$
|
1.93
|
Option Outstanding
|
||||||||||
(in 000s)
|
Weighted Average
|
Weighted Average
|
||||||||
Price Range
|
Shares
|
Exercise Price
|
Remaining Life
|
|||||||
$0.50 - $1.25
|
770
|
$
|
0.75
|
1.94
|
||||||
$1.50
- $2.50
|
1,326
|
$
|
1.90
|
5.56
|
||||||
$2.87
- $5.34
|
714
|
$
|
3.18
|
5.26
|
Options Exercisable
|
||||||||||
Weighted Average
|
Weighted Average
|
|||||||||
Price Range
|
Shares
|
Exercise Price
|
Remaining Life
|
|||||||
$0.50
- $1.25
|
769
|
$
|
0.75
|
1.94
|
||||||
$1.50
- $2.50
|
908
|
$
|
2.00
|
6.49
|
||||||
$2.87
- $5.34
|
666
|
$
|
3.21
|
5.14
|
September 26, 2008
|
March 31, 2008
|
||||||
Raw
material
|
$
|
3,610,000
|
$
|
3,260,000
|
|||
Work-in-process
|
1,309,000
|
1,626,000
|
|||||
Finished
products
|
528,000
|
229,000
|
|||||
Total
inventories
|
5,447,000
|
5,115,000
|
|||||
Less
reserve
|
(1,138,000
|
)
|
(984,000
|
)
|
|||
Inventories,
net
|
$
|
4,309,000
|
$
|
4,131,000
|
September 26, 2008
|
March 31, 2008
|
||||||||||||||||||||||||
Weighted
Average Lives |
Amortization
Method
|
Carrying
Value |
Accumulated
Amortization
|
Intangibles
Net |
Carrying
Value |
Accumulated
Amortization
|
Intangibles
Net |
||||||||||||||||||
Non-Compete
agreement
|
3
|
Cash
Flow
|
$
|
130
|
$
|
130
|
$
|
—
|
$
|
130
|
$
|
117
|
$
|
13
|
|||||||||||
Customer
list
|
15
|
Straight Line
|
475
|
328
|
147
|
475
|
322
|
153
|
|||||||||||||||||
Trademarks
|
15
|
Cash
Flow
|
2,270
|
453
|
1,817
|
2,270
|
391
|
1,879
|
|||||||||||||||||
Customer
relationships
|
5
|
Cash
Flow
|
1,380
|
588
|
792
|
1,380
|
450
|
930
|
|||||||||||||||||
Technology
|
10
|
Cash
Flow
|
10,950
|
4,411
|
6,539
|
10,950
|
3,592
|
7,358
|
|||||||||||||||||
Patents
pending
|
|
492
|
—
|
492
|
424
|
—
|
424
|
||||||||||||||||||
Patents
|
Straight
Line
|
209
|
80
|
129
|
187
|
73
|
114
|
||||||||||||||||||
Total
Intangibles
|
$
|
15,906
|
$
|
5,990
|
$
|
9,916
|
$
|
15,816
|
$
|
4,945
|
$
|
10,871
|
Intangible
Assets
|
Patents
(a)
|
|||||||||
2009
(6 months)
|
$
|
1,025,000
|
2009 (6 months) |
|
$
|
8,000
|
||||
2010
|
2,035,000
|
2010 |
16,000
|
|||||||
2011
|
1,584,000
|
2011 |
16,000
|
|||||||
2012
|
1,305,000
|
2012 |
15,000
|
|||||||
2013
|
1,088,000
|
2013 |
15,000
|
|||||||
2014
& after
|
2,258,000
|
2014 & after |
59,000
|
|||||||
Total
|
$
|
9,295,000
|
Total
|
$
|
129,000
|
a)
|
Patent
pending costs of $492,000 are not included in the chart above. These
costs
will be amortized beginning the month the patents are granted.
|
As of
|
|||||||
September 26, 2008
|
March 31, 2008
|
||||||
Capital
lease obligations
|
$
|
—
|
$
|
1,917
|
|||
Bank
term loan
|
1,736
|
—
|
|||||
Bank
line of credit
|
1,363
|
1,300
|
|||||
MEDC
loans
|
2,311
|
2,311
|
|||||
Debt
to Related Parties
|
1,851
|
1,851
|
|||||
Total
|
$
|
7,261
|
$
|
7,379
|
Three months ended
|
Six months ended
|
||||||||||||
Basic
and Diluted
|
September
26, 2008 |
September
28, 2007 |
September
26, 2008 |
September
28, 2007 |
|||||||||
Weighted
Average Basic Shares Outstanding
|
24,060,000
|
19,906,000
|
24,035,000
|
19,584,000
|
|||||||||
Net
income (loss)
|
$
|
(326,000
|
)
|
$
|
(1,857,000
|
)
|
$
|
(179,000
|
)
|
$
|
(3,763,000
|
)
|
|
Basic
earnings per share
|
$
|
(0.01
|
)
|
$
|
(0.09
|
)
|
$
|
(0.01
|
)
|
$
|
(0.19
|
)
|
Three months ended
|
Six months ended
|
||||||||||||||||||||||||
Revenues
|
September
26, 2008 |
%
|
September 28,
2007
|
%
|
September 26,
2008
|
%
|
September 28,
2007
|
%
|
|||||||||||||||||
Telecommunications
|
$
|
1,490
|
18
|
%
|
$
|
1,589
|
24
|
%
|
$
|
3,689
|
23
|
%
|
$
|
2,847
|
21
|
%
|
|||||||||
Industrial
Sensing/NDT
|
3,111
|
38
|
%
|
2,630
|
40
|
%
|
6,322
|
40
|
%
|
5,546
|
47
|
%
|
|||||||||||||
Military/Aerospace
|
2,480
|
30
|
%
|
950
|
15
|
%
|
4,243
|
27
|
%
|
1,821
|
14
|
%
|
|||||||||||||
Medical
|
492
|
6
|
%
|
1,360
|
21
|
%
|
992
|
6
|
%
|
2,460
|
18
|
%
|
|||||||||||||
Homeland
Security
|
615
|
8
|
%
|
—
|
—
|
712
|
4
|
%
|
—
|
—
|
|||||||||||||||
Total
Revenues
|
$
|
8,188
|
100
|
%
|
$
|
6,529
|
100
|
%
|
$
|
15,958
|
100
|
%
|
$
|
12,674
|
100
|
%
|
Exhibit
No.
|
|
|
31.1
|
|
Certificate
of the Registrant’s Chairman, Chief Executive Officer, and Director
pursuant to Section 302 of the Sarbanes-Oxley Act of
2002
|
|
|
|
31.2
|
|
Certificate
of the Registrant’s Chief Financial Officer, and Secretary pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
32.1
|
|
Certificate
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
32.2
|
|
Certificate
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of
2002
|
Advanced
Photonix, Inc.
|
(Registrant)
|
November
10, 2008
|
/s/
Richard Kurtz
|
Richard
Kurtz
|
Chairman,
Chief Executive Officer
|
and
Director
|
/s/
Robin Risser
|
Robin
Risser
|
Chief
Financial Officer
|
and
Director
|